Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047083 · ClinicalTrials.gov registry record
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 1,027
- Enrollment target
NCT03047083: Completed study, sponsored by Astellas Pharma Global Development.
NCT03047083 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,027 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03047083 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 1,027 participants
- Enrollment target
Study Summary
The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.
Interventions
- OTHER Treatment patterns among AML patients
- OTHER AML-related healthcare resources
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2014-06-02 |
| Est. Completion | 2016-03-18 |
What the finished NCT03047083 record still lists
NCT03047083 is an observational study that tracks outcomes without assigning an intervention. Its 1,027 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Treatment patterns among AML patients is the first listed.
NCT03047083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03047083 about?
NCT03047083 is a clinical study titled "Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review". The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.
What is the current status of trial NCT03047083?
This trial is currently completed. The enrollment target is 1,027 participants. The study started on 2014-06-02. Estimated completion is 2016-03-18.
What interventions are being tested in trial NCT03047083?
The interventions under investigation include: Treatment patterns among AML patients (OTHER), AML-related healthcare resources (OTHER).
Who is sponsoring clinical trial NCT03047083?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI